Last reviewed · How we verify
68Ga-FAPi-46
At a glance
| Generic name | 68Ga-FAPi-46 |
|---|---|
| Also known as | Gallium-68-FAPi-46 |
| Sponsor | Peter MacCallum Cancer Centre, Australia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT (NA)
- FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers (PHASE2)
- 68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases (NA)
- The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. (PHASE1)
- 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease (EARLY_PHASE1)
- Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (PHASE2)
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (PHASE1)
- Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 68Ga-FAPi-46 CI brief — competitive landscape report
- 68Ga-FAPi-46 updates RSS · CI watch RSS
- Peter MacCallum Cancer Centre, Australia portfolio CI